November 22, 2026:


Many family-doctor practices in Germany currently lack flu vaccine, the country’s main GP association said Saturday, Nov. 21, even as the federal regulator reports 20.2 million doses released this season. Both statements can be true, because the Paul-Ehrlich-Institut (PEI) counts batches that passed testing and says it is not involved in the chain from manufacturer through wholesaler to pharmacy. Anyone in a recommended group should confirm stock with a practice before counting on an appointment, because the vaccination window runs only to mid-December.
The PEI says batch testing and release began later than usual this year because all three virus strains in the 2026/27 vaccines had to be updated, an adaptation it called particularly extensive, and because some production materials arrived late. The institute told the trade publication Pharmazeutische Zeitung on Nov. 6 that it had refused release of no batch of the high-dose vaccine Efluelda or any other flu vaccine.
For patients, the gap shows up in the waiting room. Practices without stock are phoning pharmacies to find doses, and some appointments have been pushed back.
Nicola Buhlinger-Göpfarth, federal chair of the German GP association (Deutscher Hausärztinnen- und Hausärzteverband), told the Augsburger Allgemeine that vaccine was sometimes delivered far too late and sometimes not in the quantity ordered. She said this directly hinders the vaccination campaign even though vaccination rates are already far too low.
The Robert Koch-Institut (RKI) measured flu vaccination at 34.5% of people 60 and older in 2024/25, the lowest rate since 2008/09 and far below the 75% target the WHO recommends. The dpa report gives no vaccination-rate figure for the current season.
A spokesperson for the national pharmacists’ federation (Bundesvereinigung Deutscher Apothekerverbände) told the same newspaper that supply is generally secure, though individual products may occasionally sell out. The association’s account is general: the dpa report does not say how many practices are affected, which regions are worst hit, or which vaccine products are involved.
A PEI spokesperson confirmed to the Augsburger Allgemeine that batch testing and release began late and said he sees no nationwide shortage. An online graphic from the institute shows the number of tested doses in recent months ran well below previous years and has since caught up, with 20.2 million doses released.
On Nov. 6, the PEI put the count at about 19.9 million doses as of Nov. 2. That implies roughly 0.3 million more doses between the two published counts, but dpa does not say when the 20.2 million figure applies, so the dates and counting basis may not match.
Last season offers a caution about reading release totals as stock. The PEI reported about 19.1 million doses released for 2025/26 in a December 2025 notice, and at the same time reported regional shortages while saying it had no confirmed indications of a widespread shortage. GPs reported that some flu vaccines were missing by mid-December in parts of Germany that winter.
The PEI defines a supply shortage as an interruption of supply from the manufacturer to the usual extent that is expected to last more than two weeks, or an unexpected, considerably increased demand the manufacturer cannot meet. The institute also states that a manufacturer’s notice of sale of seasonal flu vaccines does not itself constitute a supply shortage.
The PEI said supply problems at individual pharmacies do not necessarily mean the vaccine is unavailable, because it is not involved in the chain from manufacturer through wholesaler to pharmacy, and it said short-term regional or local shortages are possible. A release count and a practice’s stock therefore measure different points in one supply chain. Patients, pharmacists and doctors can report a suspected shortage not on the PEI’s list through a form on its site.
The WHO announced its recommended strains for 2026-2027 Northern Hemisphere season on Feb. 27, 2026. For egg-based vaccines, they are A/Missouri/11/2025 (an H1N1 virus), A/Darwin/1454/2025 (H3N2) and B/Tokyo/EIS13-175/2025 (B/Victoria lineage), with different H3N2 and B strains named for cell-culture, recombinant and nucleic-acid vaccines. The WHO noted that a notably different H3N2 variant called subclade K emerged in August 2025 and accounted for the majority of reported influenza viruses. The CDC says all three virus components of 2026-2027 U.S. vaccines were updated from last season, and the PEI said the same adaptation applied to the vaccines for Germany.
A manufacturer has described the knock-on effect. Sanofi, which makes Efluelda and Vaxigrip, cited extensive strain adaptation and delays in providing and calibrating the reagents needed, and said the regulatory processes for annual strain adaptation also affect production schedules, according to a Baden-Württemberg physicians’ association notice dated Oct. 27. On Aug. 31, Sanofi said Efluelda deliveries were starting immediately while Vaxigrip would follow from calendar week 41, which it attributed to three strain changes and global delays in supplying reagents.
Official batch testing comes after manufacture. Every German flu vaccine is tested by an Official Medicines Control Laboratory, including the PEI, which tests randomly selected doses from each production batch, reviews the manufacturing documents and the manufacturer’s quality-control results, and grants release only if every criterion of the marketing authorization is met. The PEI attributes its late start to manufacturer delays this year.
Pharmacists reported on Nov. 6 that only a fraction of the Efluelda they ordered was arriving, and others reported significantly delayed deliveries. The dpa report on the GP association’s complaint names no product.
The PEI says flu vaccine production takes at least four to six months and that post-production is not possible. Under Germany’s statutory ordering process, the national association of statutory-insurance physicians (KBV) reports demand from GPs’ planned orders by Jan. 15 each year, the pharmacists’ organization reports pharmacy demand on the same date, and the PEI adds a 10% reserve before passing the result to manufacturers. By the PEI’s account, a practice that finds in November it needs more doses has no way to trigger a new production run, which is why an order placed about nine months earlier carries so much weight.
Practices must order flu vaccine about nine months ahead, when demand is hard to predict, and statutory health insurers can sanction them financially if they order too much. The dpa report gives no sanction amount.
The dispute is long-running. On Jan. 20, 2026, the GP association called the ordering rules extremely rigid and demanded that practices be freed from the financial risk, pointing to an early flu wave and the subclade K strain that pushed demand up in 2025/26. The KBV made a similar call on Jan. 30, saying practices order based on last season’s use and keep small reserves because surplus orders risk a review procedure and recourse claim. The KBV wants the recourse provision in paragraph 106b(1a) of the social insurance code (SGB V) deleted. That Ärzteblatt report contains no response from the federal health ministry or the insurers’ federation GKV-Spitzenverband.
The PEI and the GPs disagree about timing. On Mar. 19, 2026, the Rhineland-Palatinate branch of the GP association rejected a PEI request that family doctors order flu vaccine by the end of that month. Branch chair Barbara Römer argued that pharmacies and company doctors also vaccinate, so practices cannot reliably forecast how many patients will come to them, and suggested nationwide databases of risk groups and past-quarter vaccination figures as better planning tools. The PEI’s stated reason is that production takes several months, so orders are needed early.
Buhlinger-Göpfarth and fellow federal chair Markus Beier presented the association’s July 2024 position paper “KI in der Hausarztpraxis,” which sees large potential for AI in administration, diagnostics and patient interaction and demands market-open interfaces from practice-software vendors, a clear regulatory framework and data protection requirements. In November 2025 she rated the idea behind the electronic patient record “very good” and its implementation by insurers, industry and the digital agency Gematik “poor.” The dpa report on the vaccine shortage contains no technology proposal from the association.
The RKI recommends annual flu vaccination from October to mid-December so protection is in place before the flu wave, which usually peaks after the new year. The recommendation covers people 60 and older, people with chronic illness, pregnant women, care-home residents and medical staff, among others. Protection takes about two weeks to build, according to Germany’s health ministry, which gives 10 to 14 days.
Pharmacies have been able to give flu shots since 2022, although they account for a small share of vaccinations. The practical order is to ask the practice about stock, then check pharmacies, keeping in mind that the pharmacists’ federation says individual products can sell out and the PEI says short-term local gaps are possible.
The dpa report gives no count of affected practices, no regional breakdown and no list of products. It says tested doses ran well below previous years for months but gives no numbers, and it does not say when the 20.2 million figure applies. Claims attributed to the Augsburger Allgemeine reach readers through dpa’s account.
Both sides are probably describing the same problem from different ends. The PEI says release started late because of an unusually broad strain update and is now on track, while GPs say stock arrived late or short at the practice and that ordering rules leave them no room to react. A release count cannot confirm what is on a practice shelf, and nine-month orders cannot be topped up in November. For patients in recommended groups, that means asking the practice about stock now, checking pharmacies if it has none, and aiming to be vaccinated before the mid-December end of the recommended window.
It depends on who is counting. The GP association says many practices lack vaccine, while the PEI sees no nationwide shortage and says short-term local gaps are possible. The PEI’s formal definition of a supply shortage requires a manufacturer-level interruption expected to last more than two weeks.
Release means a batch passed official testing, and the PEI says it is not involved in distribution from manufacturer through wholesaler to pharmacy. The GP association says deliveries to practices were partly late and partly below the quantity ordered.
The RKI recommends vaccination from October to mid-December, ahead of a flu wave that usually peaks after the new year. Protection takes about two weeks to build.
Yes, pharmacies have been able to give flu shots since 2022. The pharmacists’ federation says supply is generally secure but individual products may sell out.